Shanghai Rendu (China) Performance
| 688193 Stock | 38.01 0.70 1.81% |
The entity has a beta of -0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Shanghai Rendu are expected to decrease at a much lower rate. During the bear market, Shanghai Rendu is likely to outperform the market. At this point, Shanghai Rendu Biote has a negative expected return of -0.14%. Please make sure to validate Shanghai Rendu's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if Shanghai Rendu Biote performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Shanghai Rendu Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Forward Dividend Yield 0.0077 | Payout Ratio 0.3704 | Forward Dividend Rate 0.3 | Ex Dividend Date 2024-10-30 |
1 | Shanghai Rendu Biotechnology Co., Ltd.s Business Is Trailing The Industry But Its Shares Arent - Simply Wall St | 02/10/2025 |
| Begin Period Cash Flow | 298.6 M |
Shanghai |
Shanghai Rendu Relative Risk vs. Return Landscape
If you would invest 4,292 in Shanghai Rendu Biotechnology on November 28, 2024 and sell it today you would lose (421.00) from holding Shanghai Rendu Biotechnology or give up 9.81% of portfolio value over 90 days. Shanghai Rendu Biotechnology is generating negative expected returns and assumes 2.6344% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Shanghai, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Shanghai Rendu Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Shanghai Rendu's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Shanghai Rendu Biotechnology, and traders can use it to determine the average amount a Shanghai Rendu's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0545
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 688193 |
Estimated Market Risk
| 2.63 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Shanghai Rendu is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Shanghai Rendu by adding Shanghai Rendu to a well-diversified portfolio.
Shanghai Rendu Fundamentals Growth
Shanghai Stock prices reflect investors' perceptions of the future prospects and financial health of Shanghai Rendu, and Shanghai Rendu fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Shanghai Stock performance.
| Return On Equity | 0.0227 | ||||
| Return On Asset | -0.0062 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 875.41 M | ||||
| Shares Outstanding | 40 M | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 8.50 X | ||||
| Revenue | 164.41 M | ||||
| Gross Profit | 141.86 M | ||||
| EBITDA | 2.87 M | ||||
| Net Income | 8.26 M | ||||
| Total Debt | 2.93 M | ||||
| Book Value Per Share | 23.95 X | ||||
| Cash Flow From Operations | 17.19 M | ||||
| Earnings Per Share | 0.54 X | ||||
| Total Asset | 1.05 B | ||||
| Retained Earnings | 136.46 M | ||||
About Shanghai Rendu Performance
By analyzing Shanghai Rendu's fundamental ratios, stakeholders can gain valuable insights into Shanghai Rendu's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Shanghai Rendu has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Shanghai Rendu has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Shanghai Rendu is entity of China. It is traded as Stock on SHG exchange.Things to note about Shanghai Rendu Biote performance evaluation
Checking the ongoing alerts about Shanghai Rendu for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Shanghai Rendu Biote help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Shanghai Rendu Biote generated a negative expected return over the last 90 days | |
| Shanghai Rendu Biote has high likelihood to experience some financial distress in the next 2 years | |
| About 60.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: Shanghai Rendu Biotechnology Co., Ltd.s Business Is Trailing The Industry But Its Shares Arent - Simply Wall St |
- Analyzing Shanghai Rendu's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Shanghai Rendu's stock is overvalued or undervalued compared to its peers.
- Examining Shanghai Rendu's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Shanghai Rendu's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Shanghai Rendu's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Shanghai Rendu's stock. These opinions can provide insight into Shanghai Rendu's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Shanghai Stock analysis
When running Shanghai Rendu's price analysis, check to measure Shanghai Rendu's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Rendu is operating at the current time. Most of Shanghai Rendu's value examination focuses on studying past and present price action to predict the probability of Shanghai Rendu's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Rendu's price. Additionally, you may evaluate how the addition of Shanghai Rendu to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |